Condition
Buerger Disease
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Completed1
Not Yet Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05698979Phase 3Not Yet RecruitingPrimary
Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease
NCT02501018Phase 2Completed
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
NCT00145262UnknownPrimary
TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation
Showing all 3 trials